EKF Diagnostics Holdings plc provided revenue guidance for the full year ending December 31, 2015. For the period, the company expects to achieve full year revenues of approximately £32 million. There are likely to be a number of items which will materially affect the company's profit before tax for the year, including: the partial or complete impairment of the Molecular division.

Discussions regarding the divestment or closure of the Molecular division are still ongoing; a provision against, or write off of, specific debtors; and the closure costs of the STI site in Sanford, which the company announced on November 12, 2015.